1
|
Kolbowski L, Belsom A, Pérez-López AM, Ly T, Rappsilber J. Light-Induced Orthogonal Fragmentation of Crosslinked Peptides. JACS Au 2023; 3:2123-2130. [PMID: 37654600 PMCID: PMC10466327 DOI: 10.1021/jacsau.3c00199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 08/02/2023] [Accepted: 08/03/2023] [Indexed: 09/02/2023]
Abstract
Crosslinking mass spectrometry provides pivotal information on the structure and interaction of proteins. MS-cleavable crosslinkers are regarded as a cornerstone for the analysis of complex mixtures. Yet they fragment under similar conditions as peptides, leading to mixed fragmentation spectra of the crosslinker and peptide. This hampers selecting individual peptides for their independent identification. Here, we introduce orthogonal cleavage using ultraviolet photodissociation (UVPD) to increase crosslinker over peptide fragmentation. We designed and synthesized a crosslinker that can be cleaved at 213 nm in a commercial mass spectrometer configuration. In an analysis of crosslinked Escherichia coli lysate, the crosslinker-to-peptide fragment intensity ratio increases from nearly 1 for a conventionally cleavable crosslinker to 5 for the UVPD-cleavable crosslinker. This largely increased the sensitivity of selecting the individual peptides for MS3, even more so with an improved doublet detection algorithm. Data are available via ProteomeXchange with identifier PXD040267.
Collapse
Affiliation(s)
- Lars Kolbowski
- Chair
of Bioanalytics, Technische Universität
Berlin, 10623 Berlin, Germany
| | - Adam Belsom
- Chair
of Bioanalytics, Technische Universität
Berlin, 10623 Berlin, Germany
| | - Ana M. Pérez-López
- Chair
of Bioanalytics, Technische Universität
Berlin, 10623 Berlin, Germany
| | - Tony Ly
- Wellcome
Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, U.K.
| | - Juri Rappsilber
- Chair
of Bioanalytics, Technische Universität
Berlin, 10623 Berlin, Germany
- Wellcome
Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, U.K.
- Si-M/″Der
Simulierte Mensch″, a Science Framework of Technische Universität
Berlin and Charité - Universitätsmedizin Berlin, 10623 Berlin, Germany
| |
Collapse
|
2
|
Pérez-López AM, Belsom A, Fiedler L, Xin X, Rappsilber J. Dual-Bioorthogonal Catalysis by a Palladium Peptide Complex. J Med Chem 2023; 66:3301-3311. [PMID: 36820649 PMCID: PMC10009749 DOI: 10.1021/acs.jmedchem.2c01689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Artificial metalloenzymes (ArMs) enrich bioorthogonal chemistry with new-to-nature reactions while limiting metal deactivation and toxicity. This enables biomedical applications such as activating therapeutics in situ. However, while combination therapies are becoming widespread anticancer treatments, dual catalysis by ArMs has not yet been shown. We present a heptapeptidic ArM with a novel peptide ligand carrying a methyl salicylate palladium complex. We observed that the peptide scaffold reduces metal toxicity while protecting the metal from deactivation by cellular components. Importantly, the peptide also improves catalysis, suggesting involvement in the catalytic reaction mechanism. Our work shows how a palladium-peptide homogeneous catalyst can simultaneously mediate two types of chemistry to synthesize anticancer drugs in human cells. Methyl salicylate palladium LLEYLKR peptide (2-Pd) succeeded to simultaneously produce paclitaxel by depropargylation, and linifanib by Suzuki-Miyaura cross-coupling in cell culture, thereby achieving combination therapy on non-small-cell lung cancer (NSCLC) A549 cells.
Collapse
Affiliation(s)
- Ana M Pérez-López
- Chair of Bioanalytics, Technische Universität Berlin, 10623 Berlin, Germany.,Si-M/"Der Simulierte Mensch", a Science Framework of Technische Universität Berlin and Charité─Universitätsmedizin Berlin, 10623 Berlin, Germany
| | - Adam Belsom
- Chair of Bioanalytics, Technische Universität Berlin, 10623 Berlin, Germany.,Si-M/"Der Simulierte Mensch", a Science Framework of Technische Universität Berlin and Charité─Universitätsmedizin Berlin, 10623 Berlin, Germany
| | - Linus Fiedler
- Chair of Bioanalytics, Technische Universität Berlin, 10623 Berlin, Germany.,Si-M/"Der Simulierte Mensch", a Science Framework of Technische Universität Berlin and Charité─Universitätsmedizin Berlin, 10623 Berlin, Germany
| | - Xiaoyi Xin
- Chair of Bioanalytics, Technische Universität Berlin, 10623 Berlin, Germany.,Si-M/"Der Simulierte Mensch", a Science Framework of Technische Universität Berlin and Charité─Universitätsmedizin Berlin, 10623 Berlin, Germany
| | - Juri Rappsilber
- Chair of Bioanalytics, Technische Universität Berlin, 10623 Berlin, Germany.,Si-M/"Der Simulierte Mensch", a Science Framework of Technische Universität Berlin and Charité─Universitätsmedizin Berlin, 10623 Berlin, Germany.,Wellcome Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, U.K
| |
Collapse
|
3
|
Rubio-Ruiz B, Pérez-López AM, Uson L, Ortega-Liebana MC, Valero T, Arruebo M, Hueso JL, Sebastian V, Santamaria J, Unciti-Broceta A. In Cellulo Bioorthogonal Catalysis by Encapsulated AuPd Nanoalloys: Overcoming Intracellular Deactivation. Nano Lett 2023; 23:804-811. [PMID: 36648322 PMCID: PMC9912372 DOI: 10.1021/acs.nanolett.2c03593] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 01/09/2023] [Indexed: 06/17/2023]
Abstract
Bioorthogonal metallocatalysis has opened up a xenobiotic route to perform nonenzymatic catalytic transformations in living settings. Despite their promising features, most metals are deactivated inside cells by a myriad of reactive biomolecules, including biogenic thiols, thereby limiting the catalytic functioning of these abiotic reagents. Here we report the development of cytocompatible alloyed AuPd nanoparticles with the capacity to elicit bioorthogonal depropargylations with high efficiency in biological media. We also show that the intracellular catalytic performance of these nanoalloys is significantly enhanced by protecting them following two different encapsulation methods. Encapsulation in mesoporous silica nanorods resulted in augmented catalyst reactivity, whereas the use of a biodegradable PLGA matrix increased nanoalloy delivery across the cell membrane. The functional potential of encapsulated AuPd was demonstrated by releasing the potent chemotherapy drug paclitaxel inside cancer cells. Nanoalloy encapsulation provides a novel methodology to develop nanoreactors capable of mediating new-to-life reactions in cells.
Collapse
Affiliation(s)
- Belén Rubio-Ruiz
- Edinburgh
Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
- Department
of Medicinal and Organic Chemistry and Unit of Excellence in Chemistry
Applied to Biomedicine and Environment, Faculty of Pharmacy, Campus
Cartuja s/n, University of Granada, 18071 Granada, Spain
- GENYO,
Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avda. Ilustración 114, 18016 Granada, Spain
| | - Ana M. Pérez-López
- Edinburgh
Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
- TU
Berlin, Institut für
Biotechnologie, Aufgang
17-1, Level 4, Raum 472, Gustav-Meyer-Allee 25, 13355 Berlin, Germany
| | - Laura Uson
- Instituto
de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department
of Chemical Engineering and Environmental Technologies, University of Zaragoza, 50018 Zaragoza, Spain
| | - M. Carmen Ortega-Liebana
- Edinburgh
Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
- Department
of Medicinal and Organic Chemistry and Unit of Excellence in Chemistry
Applied to Biomedicine and Environment, Faculty of Pharmacy, Campus
Cartuja s/n, University of Granada, 18071 Granada, Spain
- GENYO,
Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avda. Ilustración 114, 18016 Granada, Spain
| | - Teresa Valero
- Edinburgh
Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
- Department
of Medicinal and Organic Chemistry and Unit of Excellence in Chemistry
Applied to Biomedicine and Environment, Faculty of Pharmacy, Campus
Cartuja s/n, University of Granada, 18071 Granada, Spain
- GENYO,
Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avda. Ilustración 114, 18016 Granada, Spain
| | - Manuel Arruebo
- Instituto
de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department
of Chemical Engineering and Environmental Technologies, University of Zaragoza, 50018 Zaragoza, Spain
- Networking
Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-
BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Jose L. Hueso
- Instituto
de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department
of Chemical Engineering and Environmental Technologies, University of Zaragoza, 50018 Zaragoza, Spain
- Networking
Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-
BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Victor Sebastian
- Instituto
de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department
of Chemical Engineering and Environmental Technologies, University of Zaragoza, 50018 Zaragoza, Spain
- Networking
Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-
BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Jesus Santamaria
- Instituto
de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, 50009 Zaragoza, Spain
- Department
of Chemical Engineering and Environmental Technologies, University of Zaragoza, 50018 Zaragoza, Spain
- Networking
Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-
BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Asier Unciti-Broceta
- Edinburgh
Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.
| |
Collapse
|
4
|
Adam C, Bray TL, Pérez-López AM, Tan EH, Rubio-Ruiz B, Baillache DJ, Houston DR, Salji MJ, Leung HY, Unciti-Broceta A. A 5-FU Precursor Designed to Evade Anabolic and Catabolic Drug Pathways and Activated by Pd Chemistry In Vitro and In Vivo. J Med Chem 2022; 65:552-561. [PMID: 34979089 DOI: 10.1021/acs.jmedchem.1c01733] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
5-Fluorouracil (5-FU) is an antineoplastic antimetabolite that is widely administered to cancer patients by bolus injection, especially to those suffering from colorectal and pancreatic cancer. Because of its suboptimal route of administration and dose-limiting toxicities, diverse 5-FU prodrugs have been developed to confer oral bioavailability and increase the safety profile of 5-FU chemotherapy regimens. Our contribution to this goal is presented herein with the development of a novel palladium-activated prodrug designed to evade the metabolic machinery responsible for 5-FU anabolic activation and catabolic processing. The new prodrug is completely innocuous to cells and highly resistant to metabolization by primary hepatocytes and liver S9 fractions (the main metabolic route for 5-FU degradation), whereas it is rapidly converted into 5-FU in the presence of a palladium (Pd) source. In vivo pharmokinetic analysis shows the prodrug is rapidly and completely absorbed after oral administration and exhibits a longer half-life than 5-FU. In vivo efficacy studies in a xenograft colon cancer model served to prove, for the first time, that orally administered prodrugs can be locally converted to active drugs by intratumorally inserted Pd implants.
Collapse
Affiliation(s)
- Catherine Adam
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, EH4 2XU Edinburgh, U.K
| | - Thomas L Bray
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, EH4 2XU Edinburgh, U.K
| | - Ana M Pérez-López
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, EH4 2XU Edinburgh, U.K
| | - Ee Hong Tan
- Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow G61 1QH, U.K.,Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, U.K
| | - Belén Rubio-Ruiz
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, EH4 2XU Edinburgh, U.K
| | - Daniel J Baillache
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, EH4 2XU Edinburgh, U.K
| | - Douglas R Houston
- Institute of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh EH9 3BF, U.K
| | - Mark J Salji
- Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow G61 1QH, U.K.,Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, U.K
| | - Hing Y Leung
- Institute of Cancer Sciences, University of Glasgow, Bearsden, Glasgow G61 1QH, U.K.,Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, U.K
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, EH4 2XU Edinburgh, U.K
| |
Collapse
|
5
|
Rubio-Ruiz B, Pérez-López AM, Sebastián V, Unciti-Broceta A. A minimally-masked inactive prodrug of panobinostat that is bioorthogonally activated by gold chemistry. Bioorg Med Chem 2021; 41:116217. [PMID: 34022529 DOI: 10.1016/j.bmc.2021.116217] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/04/2021] [Accepted: 05/11/2021] [Indexed: 11/28/2022]
Abstract
The recent incorporation of Au chemistry in the bioorthogonal toolbox has opened up new opportunities to deliver biologically independent reactions in living environments. Herein we report that the O-propargylation of the hydroxamate group of the potent HDAC inhibitor panobinostat leads to a vast reduction of its anticancer properties (>500-fold). We also show that this novel prodrug is converted back into panobinostat in the presence of Au catalysts in vitro and in cell culture.
Collapse
Affiliation(s)
- Belén Rubio-Ruiz
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Edinburgh, UK.
| | - Ana M Pérez-López
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Edinburgh, UK
| | - Víctor Sebastián
- Department of Chemical Engineering, University of Zaragoza, Campus Río Ebro-Edificio I+D, C/ Poeta Mariano Esquillor S/N, 50018 Zaragoza, Spain; Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain; Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER- BBN), Madrid, Spain
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Edinburgh, UK.
| |
Collapse
|
6
|
Sebastian V, Sancho-Albero M, Arruebo M, Pérez-López AM, Rubio-Ruiz B, Martin-Duque P, Unciti-Broceta A, Santamaría J. Nondestructive production of exosomes loaded with ultrathin palladium nanosheets for targeted bio-orthogonal catalysis. Nat Protoc 2020; 16:131-163. [PMID: 33247282 DOI: 10.1038/s41596-020-00406-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 08/25/2020] [Indexed: 01/20/2023]
Abstract
The use of exosomes as selective delivery vehicles of therapeutic agents, such as drugs or hyperthermia-capable nanoparticles, is being intensely investigated on account of their preferential tropism toward their parental cells. However, the methods used to introduce a therapeutic load inside exosomes often involve disruption of their membrane, which may jeopardize their targeting capabilities, attributed to their surface integrins. On the other hand, in recent years bio-orthogonal catalysis has emerged as a new tool with a myriad of potential applications in medicine. These bio-orthogonal processes, often based on Pd-catalyzed chemistry, would benefit from systems capable of delivering the catalyst to target cells. It is therefore highly attractive to combine the targeting capabilities of exosomes and the bio-orthogonal potential of Pd nanoparticles to create new therapeutic vectors. In this protocol, we provide detailed information on an efficient procedure to achieve a high load of catalytically active Pd nanosheets inside exosomes, without disrupting their membranes. The protocol involves a multistage process in which exosomes are first harvested, subjected to impregnation with a Pd salt precursor followed by a mild reduction process using gas-phase CO, which acts as both a reducing and growth-directing agent to produce the desired nanosheets. The technology is scalable, and the protocol can be conducted by any researcher having basic biology and chemistry skills in ~3 d.
Collapse
Affiliation(s)
- Victor Sebastian
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain. .,Department of Chemical Engineering and Environmental Technologies, University of Zaragoza, Zaragoza, Spain. .,Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.
| | - María Sancho-Albero
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain.,Department of Chemical Engineering and Environmental Technologies, University of Zaragoza, Zaragoza, Spain.,Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Manuel Arruebo
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain.,Department of Chemical Engineering and Environmental Technologies, University of Zaragoza, Zaragoza, Spain.,Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Ana M Pérez-López
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK.,Institut für Biotechnologie, Technische Universität Berlin, Berlin, Germany
| | - Belén Rubio-Ruiz
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK.,Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO) and Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Granada, Spain
| | - Pilar Martin-Duque
- Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.,Instituto Aragonés de Ciencias de la Salud-Fundación Araid/IIS Aragón, Centro de Investigaciones Biomédicas de Aragón, Universidad San Jorge, Zaragoza, Spain
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Jesús Santamaría
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain.,Department of Chemical Engineering and Environmental Technologies, University of Zaragoza, Zaragoza, Spain.,Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| |
Collapse
|
7
|
Pérez-López AM, Rubio-Ruiz B, Valero T, Contreras-Montoya R, Álvarez de Cienfuegos L, Sebastián V, Santamaría J, Unciti-Broceta A. Bioorthogonal Uncaging of Cytotoxic Paclitaxel through Pd Nanosheet-Hydrogel Frameworks. J Med Chem 2020; 63:9650-9659. [PMID: 32787091 PMCID: PMC7497487 DOI: 10.1021/acs.jmedchem.0c00781] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
![]()
The
promising potential of bioorthogonal catalysis in biomedicine
is inspiring incremental efforts to design strategies that regulate
drug activity in living systems. To achieve this, it is not only essential
to develop customized inactive prodrugs and biocompatible metal catalysts
but also the right physical environment for them to interact and enable
drug production under spatial and/or temporal control. Toward this
goal, here, we report the first inactive precursor of the potent broad-spectrum
anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture
and labile to Pd catalysts. This new prodrug is effectively uncaged
in cancer cell culture by Pd nanosheets captured within agarose and
alginate hydrogels, providing a biodegradable catalytic framework
to achieve controlled release of one of the most important chemotherapy
drugs in medical practice. The compatibility of bioorthogonal catalysis
and physical hydrogels opens up new opportunities to administer and
modulate the mobility of transition metal catalysts in living environs.
Collapse
Affiliation(s)
- Ana M Pérez-López
- Cancer Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K
| | - Belén Rubio-Ruiz
- Cancer Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K
| | - Teresa Valero
- Cancer Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K
| | - Rafael Contreras-Montoya
- Departamento de Quı́mica Orgánica, Facultad de Ciencias, Universidad de Granada, Campus de Fuentenueva s/n, Granada 18002, Spain
| | - Luis Álvarez de Cienfuegos
- Departamento de Quı́mica Orgánica, Facultad de Ciencias, Universidad de Granada, Campus de Fuentenueva s/n, Granada 18002, Spain
| | - Víctor Sebastián
- Department of Chemical Engineering and Environmental Technology; Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain.,Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER- BBN), Madrid 28029, Spain
| | - Jesús Santamaría
- Department of Chemical Engineering and Environmental Technology; Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain.,Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER- BBN), Madrid 28029, Spain
| | - Asier Unciti-Broceta
- Cancer Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K
| |
Collapse
|
8
|
Torres-Sánchez C, Pérez-López AM, Alqahtani MN, Unciti-Broceta A, Rubio-Ruiz B. Design and manufacture of functional catalyst-carrier structures for the bioorthogonal activation of anticancer agents. NEW J CHEM 2019. [DOI: 10.1039/c8nj05704d] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Achieving the activation of a latent prodrug via bio-orthogonal chemistry on the catalytic surface of a tailored Ti-[Pd] device.
Collapse
Affiliation(s)
- Carmen Torres-Sánchez
- Wolfson School of Mechanical
- Electrical and Manufacturing Engineering
- Loughborough University
- Loughborough
- UK
| | - Ana M. Pérez-López
- Cancer Research UK Edinburgh Centre
- Institute of Genetics and Molecular Medicine
- The University of Edinburgh
- Edinburgh EH4 2XR
- UK
| | - Mohammad N. Alqahtani
- Wolfson School of Mechanical
- Electrical and Manufacturing Engineering
- Loughborough University
- Loughborough
- UK
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre
- Institute of Genetics and Molecular Medicine
- The University of Edinburgh
- Edinburgh EH4 2XR
- UK
| | - Belén Rubio-Ruiz
- Cancer Research UK Edinburgh Centre
- Institute of Genetics and Molecular Medicine
- The University of Edinburgh
- Edinburgh EH4 2XR
- UK
| |
Collapse
|
9
|
Bray TL, Salji M, Brombin A, Pérez-López AM, Rubio-Ruiz B, Galbraith LCA, Patton EE, Leung HY, Unciti-Broceta A. Bright insights into palladium-triggered local chemotherapy. Chem Sci 2018; 9:7354-7361. [PMID: 30542538 PMCID: PMC6237126 DOI: 10.1039/c8sc02291g] [Citation(s) in RCA: 64] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2018] [Accepted: 07/16/2018] [Indexed: 12/22/2022] Open
Abstract
The incorporation of transition metal catalysts to the bioorthogonal toolbox has opened the possibility of producing supra-stoichiometric amounts of xenobiotics in living systems in a non-enzymatic fashion. For medical use, such metals could be embedded in implantable devices (i.e. heterogeneous catalyst) to "synthesize" drugs in desired locations (e.g. in a tumour) with high specificity and for extended periods of time, overcoming the useful life limitations of current local therapy modalities directed to specific organ sites (e.g. brachytherapy, controlled release systems). To translate this approach into a bona fide therapeutic option, it is essential to develop clinically-accessible implantation procedures and to understand and validate the activation process in relevant preclinical models. Herein we report the development of a novel Pd-activatable precursor of the red-fluorescent drug doxorubicin and Pd devices of optimized size and activity. Screening in state-of-the-art cancer models provided fundamental insights into the insertion protocols, safety and stability of the devices and into the prodrug distribution profile before and after activation.
Collapse
Affiliation(s)
- Thomas L Bray
- Cancer Research UK Edinburgh Centre , Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK .
| | - Mark Salji
- Institute of Cancer Sciences , University of Glasgow , Bearsden , Glasgow G61 1QH , UK .
- CRUK Beatson Institute , Bearsden , Glasgow G61 1BD , UK
| | - Alessandro Brombin
- Cancer Research UK Edinburgh Centre , Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK .
- MRC Human Genetics Unit , Institute of Genetics & Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK
| | - Ana M Pérez-López
- Cancer Research UK Edinburgh Centre , Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK .
| | - Belén Rubio-Ruiz
- Cancer Research UK Edinburgh Centre , Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK .
| | - Laura C A Galbraith
- Institute of Cancer Sciences , University of Glasgow , Bearsden , Glasgow G61 1QH , UK .
- CRUK Beatson Institute , Bearsden , Glasgow G61 1BD , UK
| | - E Elizabeth Patton
- Cancer Research UK Edinburgh Centre , Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK .
- MRC Human Genetics Unit , Institute of Genetics & Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK
| | - Hing Y Leung
- Institute of Cancer Sciences , University of Glasgow , Bearsden , Glasgow G61 1QH , UK .
- CRUK Beatson Institute , Bearsden , Glasgow G61 1BD , UK
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre , Institute of Genetics and Molecular Medicine , University of Edinburgh , Crewe Road South , Edinburgh EH4 2XR , UK .
| |
Collapse
|
10
|
Valero T, Delgado-González A, Unciti-Broceta JD, Cano-Cortés V, Pérez-López AM, Unciti-Broceta A, Sánchez Martín RM. Drug "Clicking" on Cell-Penetrating Fluorescent Nanoparticles for In Cellulo Chemical Proteomics. Bioconjug Chem 2018; 29:3154-3160. [PMID: 30122043 DOI: 10.1021/acs.bioconjchem.8b00481] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Chemical proteomics approaches are widely used to identify molecular targets of existing or novel drugs. This manuscript describes the development of a straightforward approach to conjugate azide-labeled drugs via click chemistry to alkyne-tagged cell-penetrating fluorescent nanoparticles as a novel tool to study target engagement and/or identification inside living cells. A modification of the Baeyer test for alkynes allows monitoring the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, guaranteeing the presence of the drug on the solid support. As a proof of concept, the conjugation of the promiscuous kinase inhibitor dasatinib to Cy5-labeled nanoparticles is presented. Dasatinib-decorated fluorescent nanoparticles efficiently inhibited its protein target SRC in vitro, entered cancer cells, and colocalized with SRC in cellulo.
Collapse
Affiliation(s)
- Teresa Valero
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine , University of Edinburgh , Edinburgh EH4 2XR , United Kingdom.,GENYO, Centre for Genomics and Oncological Research , Pfizer/University of Granada/Andalusian Regional Government , PTS Granada, Avda. Ilustración 114 , 18016 Granada , Spain.,Department of Medicinal & Organic Chemistry, Faculty of Pharmacy , University of Granada , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Antonio Delgado-González
- GENYO, Centre for Genomics and Oncological Research , Pfizer/University of Granada/Andalusian Regional Government , PTS Granada, Avda. Ilustración 114 , 18016 Granada , Spain.,Department of Medicinal & Organic Chemistry, Faculty of Pharmacy , University of Granada , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Juan Diego Unciti-Broceta
- GENYO, Centre for Genomics and Oncological Research , Pfizer/University of Granada/Andalusian Regional Government , PTS Granada, Avda. Ilustración 114 , 18016 Granada , Spain.,R&D Department , NanoGetic SL , Health Science Technological Park (PTS), Avenida de la Innovación 1, Edificio BIC , 18016 Granada , Spain
| | - Victoria Cano-Cortés
- GENYO, Centre for Genomics and Oncological Research , Pfizer/University of Granada/Andalusian Regional Government , PTS Granada, Avda. Ilustración 114 , 18016 Granada , Spain.,Department of Medicinal & Organic Chemistry, Faculty of Pharmacy , University of Granada , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Ana M Pérez-López
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine , University of Edinburgh , Edinburgh EH4 2XR , United Kingdom
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine , University of Edinburgh , Edinburgh EH4 2XR , United Kingdom
| | - Rosario M Sánchez Martín
- GENYO, Centre for Genomics and Oncological Research , Pfizer/University of Granada/Andalusian Regional Government , PTS Granada, Avda. Ilustración 114 , 18016 Granada , Spain.,Department of Medicinal & Organic Chemistry, Faculty of Pharmacy , University of Granada , Campus de Cartuja s/n , 18071 Granada , Spain
| |
Collapse
|
11
|
Rubio-Ruiz B, Pérez-López AM, Bray TL, Lee M, Serrels A, Prieto M, Arruebo M, Carragher NO, Sebastián V, Unciti-Broceta A. High-Precision Photothermal Ablation Using Biocompatible Palladium Nanoparticles and Laser Scanning Microscopy. ACS Appl Mater Interfaces 2018; 10:3341-3348. [PMID: 29320154 PMCID: PMC5799879 DOI: 10.1021/acsami.7b17282] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Herein, we report a straightforward method for the scalable preparation of Pd nanoparticles (Pd-NPs) with reduced inherent cytotoxicity and high photothermal conversion capacity. These Pd-NPs are rapidly taken up by cells and able to kill labeled cancer cells upon short exposure to near-infrared (NIR) light. Following cell treatment with Pd-NPs, ablated areas were patterned with high precision by laser scanning microscopy, allowing one to perform cell migration assays with unprecedented accuracy. Using coherent Raman microscopy, cells containing Pd-NPs were simultaneously ablated and imaged. This novel methodology was combined with intravital imaging to mediate microablation of cancerous tissue in tumor xenografts in mice.
Collapse
Affiliation(s)
- Belén Rubio-Ruiz
- Cancer Research
UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom
| | - Ana M. Pérez-López
- Cancer Research
UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom
| | - Thomas L. Bray
- Cancer Research
UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom
| | - Martin Lee
- Cancer Research
UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom
| | - Alan Serrels
- MRC Centre for Inflammation Research, Queen’s Medical Research
Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom
| | - Martín Prieto
- Department of Chemical Engineering, Aragon
Institute of Nanoscience (INA), University
of Zaragoza, Campus Río
Ebro-Edificio I+D, c/Poeta Mariano Esquillor s/n, 50018 Zaragoza, Spain
| | - Manuel Arruebo
- Department of Chemical Engineering, Aragon
Institute of Nanoscience (INA), University
of Zaragoza, Campus Río
Ebro-Edificio I+D, c/Poeta Mariano Esquillor s/n, 50018 Zaragoza, Spain
- Networking
Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029 Madrid, Spain
| | - Neil O. Carragher
- Cancer Research
UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom
| | - Víctor Sebastián
- Department of Chemical Engineering, Aragon
Institute of Nanoscience (INA), University
of Zaragoza, Campus Río
Ebro-Edificio I+D, c/Poeta Mariano Esquillor s/n, 50018 Zaragoza, Spain
- Networking
Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029 Madrid, Spain
| | - Asier Unciti-Broceta
- Cancer Research
UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom
- E-mail: . Phone: 0044 131 6518500
| |
Collapse
|
12
|
Pérez-López AM, Soria-Gila ML, Marsden ER, Lilienkampf A, Bradley M. Fluorogenic Substrates for In Situ Monitoring of Caspase-3 Activity in Live Cells. PLoS One 2016; 11:e0153209. [PMID: 27168077 PMCID: PMC4864350 DOI: 10.1371/journal.pone.0153209] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Accepted: 03/26/2016] [Indexed: 02/06/2023] Open
Abstract
The in situ detection of caspase-3 activity has applications in the imaging and monitoring of multiple pathologies, notably cancer. A series of cell penetrating FRET-based fluorogenic substrates were designed and synthesised for the detection of caspase-3 in live cells. A variety of modifications of the classical caspase-3 and caspase-7 substrate sequence Asp-Glu-Val-Asp were carried out in order to increase caspase-3 affinity and eliminate caspase-7 cross-reactivity. To allow cellular uptake and good solubility, the substrates were conjugated to a cationic peptoid. The most selective fluorogenic substrate 27, FAM-Ahx-Asp-Leu-Pro-Asp-Lys(MR)-Ahx, conjugated to the cell penetrating peptoid at the C-terminus, was able to detect and quantify caspase-3 activity in apoptotic cells without cross-reactivity by caspase-7.
Collapse
Affiliation(s)
- Ana M. Pérez-López
- School of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black building, West Mains Road, Edinburgh EH9 3FJ, United Kingdom
| | - M. Lourdes Soria-Gila
- Department of Medicinal and Organic Chemistry, University of Granada, School of Pharmacy, Campus Cartuja s/n – 18071, Granada, Spain
| | - Emma R. Marsden
- School of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black building, West Mains Road, Edinburgh EH9 3FJ, United Kingdom
| | - Annamaria Lilienkampf
- School of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black building, West Mains Road, Edinburgh EH9 3FJ, United Kingdom
| | - Mark Bradley
- School of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black building, West Mains Road, Edinburgh EH9 3FJ, United Kingdom
- * E-mail:
| |
Collapse
|
13
|
Mackay M, Pérez-López AM, Bradley M, Lilienkampf A. Eliminating caspase-7 and cathepsin B cross-reactivity on fluorogenic caspase-3 substrates. Mol Biosyst 2016; 12:693-6. [PMID: 26726961 PMCID: PMC4763880 DOI: 10.1039/c5mb00730e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 12/07/2015] [Indexed: 12/11/2022]
Abstract
11 FRET-based fluorogenic substrates were constructed using the pentapeptide template Asp-Glu-X2-Asp-X1', and evaluated with caspase-3, caspase-7 and cathepsin B. The sequence Asp-Glu-Pro-Asp-Ser was able to selectively quantify caspase-3 activity in vitro without notable caspase-7 and cathepsin B cross-reactivity, while exhibiting low μM KM values and good catalytic efficiencies (7.0-16.9 μM(-1) min(-1)).
Collapse
Affiliation(s)
- Martha Mackay
- EaStCHEM, School of Chemistry, University of Edinburgh, West Mains Road, EH9 3FJ Edinburgh, UK.
| | - Ana M Pérez-López
- EaStCHEM, School of Chemistry, University of Edinburgh, West Mains Road, EH9 3FJ Edinburgh, UK.
| | - Mark Bradley
- EaStCHEM, School of Chemistry, University of Edinburgh, West Mains Road, EH9 3FJ Edinburgh, UK.
| | - Annamaria Lilienkampf
- EaStCHEM, School of Chemistry, University of Edinburgh, West Mains Road, EH9 3FJ Edinburgh, UK.
| |
Collapse
|
14
|
Jong T, Pérez-López AM, Johansson EMV, Lilienkampf A, Bradley M. Flow and Microwave-Assisted Synthesis of N-(Triethylene glycol)glycine Oligomers and Their Remarkable Cellular Transporter Activities. Bioconjug Chem 2015; 26:1759-65. [PMID: 26155805 DOI: 10.1021/acs.bioconjchem.5b00307] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- ThingSoon Jong
- School
of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black Building, King’s
Buildings,
West Mains Road, EH9 3FJ Edinburgh, United Kingdom
| | - Ana M. Pérez-López
- School
of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black Building, King’s
Buildings,
West Mains Road, EH9 3FJ Edinburgh, United Kingdom
| | - Emma M. V. Johansson
- School
of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black Building, King’s
Buildings,
West Mains Road, EH9 3FJ Edinburgh, United Kingdom
| | - Annamaria Lilienkampf
- School
of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black Building, King’s
Buildings,
West Mains Road, EH9 3FJ Edinburgh, United Kingdom
| | - Mark Bradley
- School
of Chemistry, EaStCHEM, University of Edinburgh, Joseph Black Building, King’s
Buildings,
West Mains Road, EH9 3FJ Edinburgh, United Kingdom
| |
Collapse
|
15
|
Cárdenas-Maestre JM, Pérez-López AM, Bradley M, Sánchez-Martín RM. Microsphere-based intracellular sensing of caspase-3/7 in apoptotic living cells. Macromol Biosci 2014; 14:923-8. [PMID: 24664851 DOI: 10.1002/mabi.201300525] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Revised: 01/30/2014] [Indexed: 11/10/2022]
Abstract
A novel multifunctional probe to monitor intracellular enzymatic activity in living cells is successfully developed. Their use as accurate intracellular sensors by conjugation of an internal control (that gives an extra feature to both evaluate cellular-uptake efficiency and track probes over time) is reported. In particular, a specific application of these multifunctional microspheres as sensors of caspase-3/7 to monitor apoptosis by flow cytometry is described. The preparation of these devices together with a kinetic study towards caspase-3 and caspase-7 and their evaluation as flow cytometry probe in apoptotic living cells are reported.
Collapse
|
16
|
Pérez-López AM, Cárdenas-Maestre JM, Panadero-Fajardo S, Domínguez-Seglar JF, Gómez-Vidal JA, Sánchez-Martín R. Microsphere-mediated delivery of therapeutic peptides on neuronal cells. Drug Discov Today 2010. [DOI: 10.1016/j.drudis.2010.09.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|